Skip to main navigationSkip to main content
The University of Southampton
Health Sciences

University fundraising campaign hits milestone on World Cancer Day

Published: 4 February 2016Origin: University of Southampton
Centre for Cancer Immunology
New Centre for Cancer Immunology

The University of Southampton’s £25 million campaign to build a new cancer research centre is three quarters of the way to hitting its target thanks to a grant from the Solent Local Enterprise Partnership (LEP).

The £4.5m grant will help the University build the Centre for Cancer Immunology, the first of its kind in the UK to advance research into an innovative and effective treatment for cancer.

The grant allocated through the Solent Local Growth Deal is the largest contribution made to a University backed project by the Solent LEP to date and recognises the impact the new Centre will have, not only on the local community but on a national scale.

The Centre, which will be based at Southampton General Hospital, is expected to open in 2017 and will bring world leading cancer scientists under one roof and enable interdisciplinary teams to expand clinical trials and develop lifesaving drugs.

Professor Tim Elliott, Director of the new Centre, comments: “We are delighted to reach this significant milestone in our campaign, especially by World Cancer Day, with the help of the Solent LEP. The University has made major advances in tumour immunology and immunotherapy over the past 40 years and we enjoy a strong reputation for our ‘bench to bedside’ approach. The new Centre will go a long way in helping many more people with cancer become free of the disease.”

Immunotherapy is a revolutionary new treatment, supercharging the body’s natural defences to find and destroy cancer.

The new treatments being developed by Southampton scientists, in the form of vaccines and antibodies, direct special immune cells against cancers. These ‘killer’ cells can control and shrink cancer and give long-lasting protection. The University is developing treatments to target some of the most aggressive forms of the disease including cancers of the lung and skin, and childhood neuroblastoma.

Results from clinical trials are very promising with more than 20 per cent of participants living cancer free.

Phelan Jordan
Phelan Jordan

One patient that has benefited from Southampton’s research is three-year-old Phelan Jordan. Phelan was first diagnosed with neuroblastoma when he was just 18 months old. Now aged three, Phelan is home and doing really well, following participation in an immunotherapy trial at Southampton.

George Jordan, Phelan’s father, comments: “I had no idea trials like these were being led from Southampton. This trial was a lifeline that gave us hope. It’s amazing. I would say to anyone: please consider making a donation to the campaign. It may not be about you today but it could be about your family tomorrow. Your contribution today could benefit you tomorrow.”

Gary Jeffries, Solent LEP Chairman, comments: “At the heart of our strategy to transform the Solent economy is investing in sectors where we have the potential to be truly world leading. Our investment in Southampton will build on the University's long-standing track record in innovative immunology research and the new Centre has the potential to catalyse growth right across the Solent area in new start-ups and established life science businesses."

Professor Sir Christopher Snowden, Vice-Chancellor of the University of Southampton, adds: “We are grateful to the Solent LEP for providing such a significant grant to our campaign. Our new Centre will allow us to build on our expertise and expand the research teams in Southampton to make even greater progress in developing new treatments. The next few years will see great advances in immune therapies for cancer with the University of Southampton at the very forefront of discovery.”

Find out more about it at

More information about Phelan’s story can be seen at

Privacy Settings